Lenabasum

Unassigned

New Medicines

Resunab · Dermatomyositis, skin predominant

Information

Resunab
New molecular entity
Corbus Pharmaceuticals
Corbus Pharmaceuticals

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

Cannabinoid CB2 receptor agonist without psychoactive properties with anti inflammatory properties
The estimated incidence of dermatomyositis is 9.63 cases per million population. Most commonly it occurs between ages 40 to 60 and women are affected by dermatomyositis twice as often as males [4].
Dermatomyositis, skin predominant
Oral

Resunab · Systemic sclerosis (scleroderma)

Information

Resunab
New molecular entity
Corbus Pharmaceuticals
Corbus Pharmaceuticals

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

Cannabinoid CB2 receptor agonist without psychoactive properties that inibits fibrosis
Scleroderma is a complex, multi-system disease with significant risk of serious complications. It is uncommon, and incidence and prevalence of scleroderma varies widely around the world [2]. UK current incidence is 3.7 per million and prevalence 31-88 per million, with peak age of onset of 40 to 50 years [3].
Systemic sclerosis (scleroderma)
Oral